Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2022

Open Access 01-12-2022 | Hypercholesterolemia | Case report

Acute coronary syndrome in an 8-year-old child with familial hypercholesterolemia: a case report

Authors: Nan Wang, Ying Wei, Gang Zhou, Yue Zhang, Jiyang Song

Published in: Journal of Medical Case Reports | Issue 1/2022

Login to get access

Abstract

Background

Familial hypercholesterolemia (FH) is the most commonly inherited metabolic disease and has an autosomal dominant mode of inheritance. Patients with FH usually present with high levels of low-density lipoprotein-cholesterol, xanthomas and early coronary artery disease. Children with FH are subject to developing early and enhanced atherosclerosis, leading to an increased risk of coronary events. We report here an 8-year-old patient with acute coronary syndrome (ACS) who was diagnosed with homozygous FH (HoFH) due to mutations in the low-density lipoprotein receptor (LDLR) gene and subsequently treated with percutaneous transluminal coronary angioplasty (PTCA) after filtration plasma. To the best of our knowledge, this patient is the youngest case of HoFH treated with filtration plasma followed by PTCA reported to date.

Case presentation

An 8-year-old Asian patient was admitted to Gansu Provincial Hospital presenting symptoms of ACS. Laboratory tests showed that the patient’s cholesterol and low-density lipid levels were extremely high. An electrocardiogram (ECG) revealed sinus arrhythmia and electric axis deviation to the right, but the ECG was roughly normal. Multiple cardiac function abnormalities were diagnosed on the ECG. Multiple sites of coronary artery stenosis were determined by computed tomography angiography. DNA sequencing of exons showed a C-to-A substitution at nucleotide 126 in exon 2, resulting in a LDLR mutation in the patient and seven other family members. Following combination treatment with lipid-lowering drugs, anti-thrombosis drugs, filtration plasma and PTCA, the patient’s symptoms were significantly improved and the patient discharged.

Conclusion

We report the rare case of a patient with ACS attributable to HoFH who was treated with PTCA following filtration plasma. The patient was shown to have clinically diagnosed and molecularly confirmed HoFH that resulted from a mutation in the LDLR gene. Children with HoFH have higher risk of early coronary events and death from myocardial infarction due to premature atherosclerosis than adults. Earlier intervention and treatment will bring great benefits to the long-term survival of pediatric patients.
Literature
1.
go back to reference Harada-Shiba M, Arai H, Oikawa S, et al.. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb. 2012;19(12):1043–60.CrossRef Harada-Shiba M, Arai H, Oikawa S, et al.. Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb. 2012;19(12):1043–60.CrossRef
2.
go back to reference Migliara G, Baccolini V, Rosso A, et al. Familial hypercholesterolemia: a systematic review of guidelines on genetic testing and patient management. Front Public Health. 2017;5:252.CrossRef Migliara G, Baccolini V, Rosso A, et al. Familial hypercholesterolemia: a systematic review of guidelines on genetic testing and patient management. Front Public Health. 2017;5:252.CrossRef
3.
go back to reference Shin DG, Han SM, Kim DI, et al. Clinical features of familial hypercholesterolemia in Korea: predictors of pathogenic mutations and coronary artery disease—a study supported by the Korean Society of Lipidology and Atherosclerosis. Atherosclerosis. 2015;243(1):53–8.CrossRef Shin DG, Han SM, Kim DI, et al. Clinical features of familial hypercholesterolemia in Korea: predictors of pathogenic mutations and coronary artery disease—a study supported by the Korean Society of Lipidology and Atherosclerosis. Atherosclerosis. 2015;243(1):53–8.CrossRef
4.
go back to reference Tada H, Okada H, Nomura A, et al. Rare and deleterious mutations in ABCG5/ABCG8 genes contribute to mimicking and worsening of familial hypercholesterolemia phenotype. Circ J. 2019;83(9):1917–24.CrossRef Tada H, Okada H, Nomura A, et al. Rare and deleterious mutations in ABCG5/ABCG8 genes contribute to mimicking and worsening of familial hypercholesterolemia phenotype. Circ J. 2019;83(9):1917–24.CrossRef
5.
go back to reference EAS Familial Hypercholesterolaemia Studies Collaboration; Vallejo-Vaz AJ, De Marco M, Stevens CAT, , et al. Overview of the current status of familial hypercholesterolaemia care in over 60 countries—the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis. 2018;277:234–55. EAS Familial Hypercholesterolaemia Studies Collaboration; Vallejo-Vaz AJ, De Marco M, Stevens CAT, , et al. Overview of the current status of familial hypercholesterolaemia care in over 60 countries—the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis. 2018;277:234–55.
6.
go back to reference Do R, Stitziel NO, Won HH, et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. 2015;518(7537):102–6.CrossRef Do R, Stitziel NO, Won HH, et al. Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. Nature. 2015;518(7537):102–6.CrossRef
7.
go back to reference Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am College Cardiol. 2014;64(24):e139–228.CrossRef Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am College Cardiol. 2014;64(24):e139–228.CrossRef
8.
go back to reference Harada-Shiba M, Arai H, Ishigaki Y, et al. Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017. J Atheroscler Thromb. 2018;25(8):751–70.CrossRef Harada-Shiba M, Arai H, Ishigaki Y, et al. Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017. J Atheroscler Thromb. 2018;25(8):751–70.CrossRef
9.
go back to reference Tada H, Nomura A, Yamagishi M, Kawashiri MA. First case of sitosterolemia caused by double heterozygous mutations in ABCG5 and ABCG8 genes. J Clin Lipidol. 2018;12(5):1164-1168 e1164.CrossRef Tada H, Nomura A, Yamagishi M, Kawashiri MA. First case of sitosterolemia caused by double heterozygous mutations in ABCG5 and ABCG8 genes. J Clin Lipidol. 2018;12(5):1164-1168 e1164.CrossRef
10.
go back to reference Page MM, Bell DA, Hooper AJ, Watts GF, Burnett JR. Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children. Best Pract Res Clin Endocrinol Metab. 2014;28(3):387–403.CrossRef Page MM, Bell DA, Hooper AJ, Watts GF, Burnett JR. Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children. Best Pract Res Clin Endocrinol Metab. 2014;28(3):387–403.CrossRef
11.
go back to reference Gidding SS. The complexities of homozygous familial hypercholesterolemia management. Pediatr Transplant. 2016;20(8):1020–1.CrossRef Gidding SS. The complexities of homozygous familial hypercholesterolemia management. Pediatr Transplant. 2016;20(8):1020–1.CrossRef
12.
go back to reference Bjelakovic B, Stefanutti C, Pisciotta L, Watts G, Bejiqi R. Homozygous familial hypercholesterolaemia in childhood—the first case report in Southeast Europe. Atheroscler Suppl. 2019;40:122–4.CrossRef Bjelakovic B, Stefanutti C, Pisciotta L, Watts G, Bejiqi R. Homozygous familial hypercholesterolaemia in childhood—the first case report in Southeast Europe. Atheroscler Suppl. 2019;40:122–4.CrossRef
13.
go back to reference France M, Rees A, Datta D, et al. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. Atherosclerosis. 2016;255:128–39.CrossRef France M, Rees A, Datta D, et al. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. Atherosclerosis. 2016;255:128–39.CrossRef
14.
go back to reference Mohd Nor NS, Al-Khateeb AM, Chua YA, Mohd Kasim NA, Mohd Nawawi H. Heterozygous familial hypercholesterolaemia in a pair of identical twins: a case report and updated review. BMC Pediatr. 2019;19(1):106.CrossRef Mohd Nor NS, Al-Khateeb AM, Chua YA, Mohd Kasim NA, Mohd Nawawi H. Heterozygous familial hypercholesterolaemia in a pair of identical twins: a case report and updated review. BMC Pediatr. 2019;19(1):106.CrossRef
15.
go back to reference Ito MK, Watts GF. Challenges in the diagnosis and treatment of homozygous familial hypercholesterolemia. Drugs. 2015;75(15):1715–24.CrossRef Ito MK, Watts GF. Challenges in the diagnosis and treatment of homozygous familial hypercholesterolemia. Drugs. 2015;75(15):1715–24.CrossRef
16.
go back to reference Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128(19):2113–20.CrossRef Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128(19):2113–20.CrossRef
17.
go back to reference Roth EM, Davidson MH. PCSK9 inhibitors: mechanism of action, efficacy, and safety. Rev Cardiovasc Med. 2018;19(S1):S31–46.CrossRef Roth EM, Davidson MH. PCSK9 inhibitors: mechanism of action, efficacy, and safety. Rev Cardiovasc Med. 2018;19(S1):S31–46.CrossRef
Metadata
Title
Acute coronary syndrome in an 8-year-old child with familial hypercholesterolemia: a case report
Authors
Nan Wang
Ying Wei
Gang Zhou
Yue Zhang
Jiyang Song
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2022
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-022-03488-3

Other articles of this Issue 1/2022

Journal of Medical Case Reports 1/2022 Go to the issue